Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

COVID-19 convalescent plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19. Results from randomized control trials and observational studies have failed to demonstrate a clear therapeutic role for CCP for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartelt, Luther A., Markmann, Alena J., Nelson, Bridget, Keys, Jessica, Root, Heather, Henderson, Heather I., Kuruc, JoAnn, Baker, Caroline, Bhowmik, D. Ryan, Hou, Yixuan J., Premkumar, Lakshmanane, Cornaby, Caleb, Schmitz, John L., Weiss, Susan, Park, Yara, Baric, Ralph, de Silva, Aravinda M., Lachiewicz, Anne, Napravnik, Sonia, van Duin, David, Margolis, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601237/
https://www.ncbi.nlm.nih.gov/pubmed/36135380
http://dx.doi.org/10.1128/mbio.01751-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601237/
https://www.ncbi.nlm.nih.gov/pubmed/36135380
http://dx.doi.org/10.1128/mbio.01751-22

Ejemplares similares